Drugs and patents in ATC class A11C - VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO

Last updated: June 9, 2026

ATC A11C (Vitamin A and D, including combinations) is dominated by small-molecule, commodity-style active ingredients (vitamin A derivatives and vitamin D products). Patent value is concentrated in specific dosage forms, delivery systems (including oil-based and microencapsulated formats), manufacturing processes, and method-of-use claims tied to particular therapeutic regimens. Exclusivity typically ends along a mix of new-molecular-entity (NME) timelines for specific derivatives and later-life formulation extensions that frequently face generic and cross-licensing behavior rather than sustained litigation.

What patents protect ATC A11C vitamin A and vitamin D products?

Short answer: Patent protection across A11C is usually fragmented by product line. Core active ingredients (vitamin A and vitamin D) commonly have limited enforceable patent coverage in most jurisdictions, while brand differentiation is protected by (1) formulation patents, (2) manufacturing method patents, and (3) use/therapeutic regimen patents for specific populations or dosing strategies.

How many patents cover vitamin A vs vitamin D products in A11C?

A11C coverage is usually uneven because the market splits by derivative and brand:

Vitamin A derivatives: retinol, retinal, retinyl esters, tretinoin-class agents (outside pure “vitamin” scope in some classifications), and stabilizer-containing supplement formats.
Vitamin D products: cholecalciferol (D3), ergocalciferol (D2), calcifediol, calcitriol, and analogs (often classified outside supplements depending on jurisdiction), plus combinations with vitamin A.

Practically, active-ingredient patents for parent compounds are largely expired or very old; modern patent estates most often originate from:

Specific chemical modifications (where still relevant for some derivatives)
High-bioavailability delivery systems
Fixed-dose combinations (vitamin A + vitamin D) and their tablet/capsule oil matrices
Stability systems for oxidation/light/moisture protection

Which claim types dominate the A11C patent estate?

For A11C, the highest-frequency and highest-impact claim categories are:

Formulation: specific excipient blends, oil vehicle design, emulsions/softgel structures, microencapsulation matrices, antioxidants, and stabilizers.
Process: granulation, mixing, encapsulation, sterilization/bioburden steps (where applicable), and solvent-free or low-residue manufacturing.
Dosage regimen / method-of-use: dosing schedules tied to deficiency correction, bone health outcomes, or pregnancy/elderly risk profiles.
Packaging stability: sometimes tied to oxygen barrier and light protection designs (less common as enforceable claims, but shows up in families).

Key patent holders by category (how to think about enforceability)

A11C patent ownership typically clusters into two sets:

Originator vitamin brands and supplement incumbents (often European and US OTC-focused).
Specialty formulation and contract manufacturing technology owners (delivery systems, microencapsulation processes, softgel platforms).

In litigation outcomes for A11C-type products, the enforceable leverage often comes from a small number of late-formulation or process claims rather than broad ingredient claims.

When does exclusivity end for ATC A11C vitamin A and vitamin D products?

Short answer: Exclusivity ends along (1) patent term (20 years from earliest filing, adjusted in some countries), (2) supplementary protection certificates (SPCs) where applicable to selected vitamin D medicinal products, and (3) regulatory exclusivity (where the product is a “new drug product” under the relevant framework). For combination products, exclusivity typically survives longer due to fixed-dose formulation and stability patents.

What are the main exclusivity timelines affecting A11C?

For decision-making, treat exclusivity as three layers:

API patent term: often expired or near-expired for parent vitamins.
Derivative patent term: depends on whether the vitamin product is a derivative (calcitriol, calcifediol, or analog) with a newer filing date.
Formulation and manufacturing patents: commonly extend into later years, especially for:
- softgels and oil-based emulsions
- microencapsulation
- high-throughput manufacturing process improvements
- stability-optimized excipients and antioxidant systems

How do SPCs shift vitamin D product timelines?

Where SPCs exist for specific medicinal products containing regulated vitamin D derivatives, they can extend protection by years beyond basic patent expiry. This creates a two-stage profile:

earlier API expiry
later formulation/process/SCP-delivered protection expiry

How do fixed-dose combination patents change the “first generic” risk window?

Combination products (vitamin A + vitamin D) tend to have:

stronger formulation claim coverage (fixed-dose ratio, vehicle composition, stability strategy)
fewer straightforward “design-around” options without changing excipients or delivery format
more frequent patent coverage in the combination itself (how the two actives are stabilized and released)

What generic entry risks exist for vitamin A and vitamin D combinations (ATC A11C)?

Short answer: The most common generic entry barrier is not the active ingredient. It is the delivery system and stability-focused formulation/process patents that affect bioavailability and product performance.

What is the typical regulatory path for A11C generics?

For US decision-making, most oral vitamin supplement generics and follow-on versions often rely on abbreviated pathways if the reference is an approved drug product. Patent challenge risk materializes when a generic applicant seeks approval that would fall within existing listed Orange Book patents.

For EU and UK, the risk pattern is similar: generic or hybrid approvals can be blocked by existing national validity/infringement realities tied to formulation/process and “protected medicinal product” concepts.

Paragraph IV challenge likelihood in A11C

Paragraph IV filings are most plausible when:

there is a listed patent covering a formulation or process
the reference product is a prescription vitamin D derivative product (not just OTC supplements)
the sponsor’s remaining patent life is material to launch economics

For commodity-like vitamin A and D, paragraph IV is less frequent if the remaining patent landscape is thin or dominated by old patents with weak enforceability.

Design-around strategies that generics use

Design-around tactics for A11C formulation/process coverage usually involve:

changing oil vehicle/excipient blend
altering encapsulation method or shell composition
changing manufacturing process parameters that avoid literal infringement
changing dissolution/release profile to fall outside claim limitations
licensing formulation technology from an incumbent

What is the Orange Book status of ATC A11C vitamin A and vitamin D products?

Short answer: Orange Book status is product-specific. A11C as an ATC class does not map cleanly to a single Orange Book listing profile. Some vitamin D medicinal products have extensive Orange Book coverage (formulation and process), while others have minimal or no listed patents at the product level.

Actionable implication: Launch timing for a generic buyer or partner requires product-by-product Orange Book review, because enforcement risk is driven by listed patents at the reference drug level, not by ATC grouping.

Which patent estate is stronger: vitamin A products or vitamin D products in A11C?

Short answer: Vitamin D products often carry stronger remaining patent estates where they include more regulated derivatives (calcifediol, calcitriol) and proprietary formulations. Vitamin A products often show weaker patent tail coverage unless the product is tied to a specific delivery system or a combination fixed-dose format.

Comparison: market-typical patent coverage drivers

Vitamin D derivatives: more likely to have later-life formulation, SPC-linked extensions, and patient-subgroup dosing regimens.
Vitamin A supplements: more likely to be built on stable, commoditized excipients and generic-friendly formats, unless a branded delivery system is protected.

What formulations are protected by patents in A11C vitamin A and D combinations?

Short answer: Patents most often protect oil-based stability and release characteristics, especially in softgel/capsule delivery.

Common protected formulation elements

Vehicle: specific oils, emulsifiers, and structured lipid blends.
Stabilizers/antioxidants: protecting against oxidation of vitamin A and preventing degradation of vitamin D in light/oxygen.
Encapsulation: microencapsulation or softgel shell compositions that control permeability and release.
Fixed ratio and dosing: especially in “A + D” combination products where ratio stability is a known issue.

Dosage forms that attract the most patents

Softgels (oil matrices)
Microencapsulated powders in capsules or tablets
Dispersible or emulsified formats where bioavailability differs

What method-of-use patents cover ATC A11C vitamin D and vitamin A?

Short answer: Method-of-use coverage appears more often in medicinal vitamin D derivatives than in simple supplements, and it is typically tied to clinically defined dosing regimens or patient groups.

Typical method-of-use claim themes

correction of vitamin D deficiency in defined populations
bone health support regimens with specified dosing frequency
combination regimens involving vitamin A and vitamin D for specific therapeutic goals

What patent litigation affects vitamin A and vitamin D products in A11C?

Short answer: Litigation tends to cluster around late-cycle formulation/process patents and Orange Book-listed patents tied to prescription vitamin D products and their generics. For pure supplement markets, enforcement is often limited, and disputes skew toward trade dress or formulation rights rather than full Hatch-Waxman patent fights.

How to interpret litigation signals for investors/licensing

If litigation is ongoing near expiry, the remaining enforceable claim set often narrows to formulation or process claims.
Settlement patterns for vitamin-related products frequently involve delayed launches, design-around, or cross-licensing of formulation technology rather than invalidation of the core patent estate.

What licensing deals and settlements shape A11C market entry?

Short answer: Licensing and settlement behavior is product-specific, but the recurring commercial pattern is a technology license (formulation/process) or an agreed launch date tied to patent expiry.

Where licensing is most likely

proprietarily stabilized softgel delivery systems
microencapsulation technology
fixed-dose combination ratios that are difficult to replicate without stability tradeoffs

How does FDA status (approved drug vs supplement) change the patent landscape for A11C?

Short answer: FDA “drug product” status increases the probability that:

product-level patents appear in FDA’s patent listings (for US decision-making)
abbreviated approvals (and patent certifications) apply
exclusivity and enforcement mechanisms are structured around the approved drug reference

FDA “dietary supplement” status reduces predictability of patent lists and typically shifts disputes into general IP enforcement rather than Hatch-Waxman mechanics.

Which companies dominate the A11C competitive landscape for vitamins A and D combinations?

Short answer: The competitive landscape splits into:

brand and originator vitamin D and combination products (often with strong formulation estates)
generics and OTC incumbents offering broadly equivalent dosage forms
specialized softgel and encapsulation technology providers (frequently behind multiple brands)

Commercial implication: For market entry, analyze the reference product’s patent list and delivery system, then map which generic applicants have the capability to manufacture the relevant stability-preserving format.

Timeline view: How A11C exclusivity typically unwinds (framework for diligence)

Short answer: Treat exclusivity as a layered unwind:

API/early derivative patent expiry
formulation and process patent expiry
SPC/risk-tail extensions (where applicable)
residual stability and minor formulation tweaks that may have their own patent filings

This produces a staggered launch opportunity window for competitors, with the late-stage bottleneck usually the delivery system and stability patents.

Key tables for diligence (what to extract per product)

Because A11C is an ATC umbrella, the enforceable landscape must be built at the product level. Use the structure below for each vitamin A and vitamin D (including combination) product under review.

Table 1: Product-level patent diligence fields (extract for each reference drug)

Field	What to capture	Why it matters
Active(s) and strength	vitamin A form + vitamin D form, mg/IU	claim scope and design-around
Dosage form	softgel, tablet, capsule, microencap	formulation/process infringement
Patent numbers and assignees	US and key jurisdictions	ownership and prosecution history
Earliest priority filing date	family start	term and SPC eligibility
Expiration date	with adjustments where applicable	launch timing
Claim type (formulation/process/use)	map to infringement likelihood	litigation probability
FDA status and patent listings	Orange Book or equivalent	generic challenge routes

Table 2: Generic risk scoring (A11C typical)

Factor	Higher risk indicator
Remaining formulation/process patents	yes
Fixed-dose combination packaging and stability claims	yes
Derivative vitamin D with clinical dosing claims	yes
Multiple jurisdictions with enforceable claims	yes
Prior litigation/settlement on same family	yes

Key Takeaways

ATC A11C patent value is concentrated in formulation, manufacturing, and regimen claims, not in parent vitamin A/D molecules.
Exclusivity timing is staggered: earliest API expiry often gives way to later-life delivery system and stability patents.
Combination products (vitamin A + vitamin D) typically carry stronger formulation-specific barriers for generics because stability and fixed ratio constraints limit design-around.
Generic entry risk is product-specific and driven by whether formulation/process patents are listed for the reference drug under the applicable regulatory framework.
Litigation and settlement behavior, when it occurs, usually targets late-cycle formulation or process claims and often ends in delayed launches or design-around/cross-licensing.

FAQs

How do softgel and microencapsulation patents for vitamin D affect generic launch timing?
What types of stability and excipient claims most often survive in vitamin A and D patent challenges?
Do fixed-dose vitamin A + vitamin D combination products face different Hatch-Waxman risk than single-ingredient products?
Which jurisdictional mechanisms most extend protection for vitamin D derivatives: SPCs or patent term adjustments?
How does switching from an oil-based vehicle to a different delivery system change infringement risk for A11C?

References

European Medicines Agency (EMA). European Public Assessment Reports (EPARs) and product information for vitamin D medicinal products.
U.S. Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
FDA. Regulatory exclusivity and drug approval pathways documentation.
World Intellectual Property Organization (WIPO). Patent term basics and supplementary protection concepts (jurisdiction-dependent overviews).

Drugs in ATC Class A11C

Subclasses in ATC: A11C - VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO

Market and Patent Landscape for ATC A11C (Vitamin A and D, Including Combinations): Which Patents Protect Formulations, When Exclusivity Ends, and What Generic/Biosimilar Risk Exists